# Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

> **NCT06744504** · PHASE3 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 300 (estimated)

## Conditions studied

- AML
- RUNX1-RUNX1T1 Fusion Protein Expression

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin
- **DRUG:** idarubicin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT06744504
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2027-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744504, "Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06744504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*